Advocacy
Make your voice heard. Learn about PDAB legislation and implementation processes across the country.
Legislation
Delaware: SJR 7
Directs the State Employee Benefits Committee to utilize strategies to lower prescription drug costs for the State, including Medicare MFP reference pricing.
5/9/25 – Introduced as SJR 7 and Assigned to Senate Health & Social Services Committee
5/14/25 – Reported Out of Committee
5/21/25 – SS 1 Substituted for SJR 7
5/21/25 – PASSED Senate: 19 YES – 0 NO
5/22/25 – Assigned to Administration Committee in House
6/25/25 – Reported Out of Committee
Illinois: HB 1443 / SB 66
Establishes the Health Care Availability and Access Board
HB 1443
1/17/25 – Introduced
1/28/25 – Referred to Rules Committee
2/18/25 – Assigned to Health Care Availability & Access Committee
2/25/25 – Assigned to Prescription Drug Affordability Board Subcommittee
3/21/25 – Deadline Passed – Re-referred to Rules Committee
SB 66
1/13/25 – Introduced and Referred to Committee on Assignments.
Iowa: SF 264
Creates a Prescription Drug Affordability Board.
SF 264
2/11/25 – Introduced
3/7/25 – Committee deadline – no action taken
Kansas: SB 212
Establishes a Prescription Drug Affordability Board
2/6/25 – Referred to Committee on Financial Institutions and Insurance
Maine: LD 697
Directs the Prescription Drug Affordability to assess strategies, including upper payment limits and reference-based pricing, to lower prescription drug costs.
2/22/25 – Referred to Committee on Health Coverage, Insurance and Financial Services
Maryland: HB424 / SB357
Requiring the Prescription Drug Affordability Board, under certain circumstances, to establish a process for setting upper payment limits for all purchases and payor reimbursements of prescription drug products in the State that the Board determines have led or will lead to affordability challenges.
HB 424
1/16/25 – Referred to Health and Government Operations Committee
2/18/25 – Reported Favorably with Amendments
2/21/25 – PASSED House: 94 YES – 38 NO
2/24/25 – Referred to Senate Finance Committee
4/4/25 – Reported Favorably with Amendments
4/4/25 – PASSED Senate: 33 YES – 12 NO
4/7/25 – House Concurs / PASSED: 100 YES – 38 NO
SB 357
1/16/25 – Referred to Finance Committee
3/10/25 – Reported Favorably with Amendment
3/12/25 – PASSED Senate: 35 YES – 12 NO
3/13/25 – Referred to House Health and Government Operations Committe
4/1/25 – Reported Favorably with Amendments
4/7/25 – PASSED House: 102 YES – 38 NO
4/7/25 – Senate Concurs / PASSED: 32 YES – 11 NO
Michigan: SB 3
Prescription Drug Cost and Affordability Review Act
Establishes a Prescription Drug Affordability Board.
1/8/25 – Introduced and Referred to Committee on Finance, Insurance, and Consumer Protection
4/24/25 – Reported Favorably with Substitute
4/24/25 – PASSED Senate: 20 YES – 15 NO
4/24/25 – Referred to House Committee on Government Operations
Nevada: AB 259
Implements reference pricing for certain prescription drugs.
2/19/25 – Introduced and Referred to Assembly Committee on Commerce and Labor
4/16/25 – Reported Favorably
4/17/25 – Referred to Assembly Committee on Ways and Means
5/27/25 – Reported Favorably
5/27/25 – PASSED Assembly: 27 YES – 15 NO
5/28/25 – Referred to Senate Finance Committee
5/30/25 – Reported Favorably
6/2/25 – PASSED Senate: 13 YES – 8 NO
6/12/25 – VETOED by Governor
Rhode Island: S0468 / H5860
Implements reference pricing for certain prescription drugs.
S0468
2/26/25 – Introduced and Referred to Health and Human Services Committee
3/20/25 – Committee recommends measure be held for further study
5/6/25 – Committee recommends passage
H5860
2/28/25 – Introduced and Referred to Health and Human Services Committee
3/6/25 – Committee recommends the bill be held for further study
Virginia: HB 1724
Establishes a Prescription Drug Affordability Board.
1/4/25 – Introduced and referred to Committee on Labor and Commerce
1/14/25 – PASSED and referred to Appropriations Committee: 12 YES – 9 NO
1/24/25 – PASSED Appropriations – Health & Human Resources Subcommittee: 5 YES – 2 NO
1/31/25 – PASSED House – 52 YES – 44 NO
2/3/25 – Referred to Senate Committee on Commerce and Labor
2/10/25 – PASSED Senate Committee on Commerce and Labor: 10 YES – 5 NO
2/14/25 – PASSED Senate Committee on Finance and Appropriations: 10 YES – 4 NO
2/18/25 – PASSED Senate with Substitute: 26 YES – 14 NO
2/19/25 – PASSED House agreed with Senate Substitute: 52 YES – 45 NO
3/24/25 – VETOED by Governor
West Virginia: HB 2831
Establishes a Prescription Drug Affordability Board.
2/24/25 – Introduced and Referred to Health and Human Resources Committee
Implementation
Colorado Prescription Drug Affordability Board
Next Regular Meeting: July 11, 2025 – 10AM MDT
Register HERE
Agenda: Second Rulemaking Hearing for Enbrel UPL
Previous Findings:
Trikafta – Not Unaffordable
Genvoya – Not Unaffordable
Enbrel – Unaffordable
Stelara – Unaffordable
Cosentyx – Unaffordable
The Board is considering plans for setting upper payment limits for drugs deemed unaffordable.
Maryland Prescription Drug Affordability Board
Next Regular Board Meeting: July 28, 2025
Agenda TBD
At the May 2024 meeting, the PDAB selected six drugs for cost review:
Farxiga
Jardiance
Ozempic
Trulicity
Dupixent
Skyrizi
Data has been collected and reports reports being prepared for comment and consideration.
Oregon Prescription Drug Affordability Board
Next Meeting: July 16 – 9AM PDT
Register HERE
In June 2024, the board voted to pause current assessments in order to reevaluate their process and data, with assessments resuming in 2025. In March 2025, the PDAB selected 27 drugs to review. In June 2025, the list was narrowed to 23 drugs.
2024 Findings:
Ozempic – May Cause Affordability Challenges (2/21)
Trulicity – May Cause Affordability Challenges (2/21)
Shingrix- Reviewed, No Motion to Add to List of Drugs That May Cause Affordability Challenges (2/21)
Inflectra – Removed from Affordability Review (5/15)
Skyrizi – Removed from Affordability Review (5/15)
Washington Prescription Drug Affordability Board
Next Meeting: July 15, 2025
Agenda TBD
© 2024 Value of Care Coalition
Washington, DC 20006